Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Nivolumab (Nivolumab, trade name Opdivo, Chinese trade name Opdivo, Ono Pharmaceutical’s licensed version trade name Baoshifu) is a fully humanized anti-PD-1 monoclonal antibody used to treat cancer. [1][2] The drug is mainly used as a first-line drug in combination with Ipilimumab to treat unresectable or metastatic melanoma, and as a second-line drug in combination with BRAF inhibitors (such as vemurafenib) to treat patients with BRAF mutations in melanoma. [3] The drug is also used as a second-line treatment for squamous non-small cell lung cancer [4] and renal cell carcinoma. [5] Nivolumab, as an immune checkpoint inhibitor, can block PD-1, thereby enabling the immune system to clear cancer. The drug was jointly developed by Medarex and Ono Pharmaceuticals. Bristol-Myers Squibb acquired Medarex and Ono Pharmaceuticals in 2009 and obtained the patent for the drug. The drug is the first PD-1 inhibitor to be included in the World Health Organization’s Model List of Essential Medicines.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.